<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771405</url>
  </required_header>
  <id_info>
    <org_study_id>4/2016</org_study_id>
    <nct_id>NCT02771405</nct_id>
  </id_info>
  <brief_title>Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC</brief_title>
  <acronym>FRI-STC</acronym>
  <official_title>Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Hepatology &amp; Tropical Medicine Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Hepatology &amp; Tropical Medicine Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will recruit 150 patients with HCV related HCC ,after HCC treatment the patients
      will undergo treatment with different regimens of DAAs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will recruit 150 patients with HCV related HCC All the studied patients underwent
      or will undergo one of the curative interventions for HCC either hepatic resection or thermal
      ablation .

      after 1 month of achievement of laboratory and radiological response to HCC intervention the
      patient will be treated with one of the interferon free regimens :

        1. Sofosbuvir+Ribavirin

        2. Sofosbuvir+Simeprevir± Ribavirin

        3. Sofosbuvir+ Daclatasvir ± Ribavirin

        4. Sofosbuvir+ Ledipasvir ± Ribavirin

      the treatment duration will be justified either 12 or 24 weeks after treatment the patient
      will continue on regular follow up to detect HCV cure or recurrence , HCC cure or recurrence
      and long term follow up of natural history
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment</measure>
    <time_frame>12 weeks after the last dose of study drugs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with virologic failure during treatment or relapse after treatment</measure>
    <time_frame>from baseline until 12 weeks after the last dose of study drugs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who will show any radiological or laboratory changes denoting local or denovo recurrence of HCC</measure>
    <time_frame>Follow up will be done from baseline for up to 36 months for detection of sustained HCC treatment,tumoral progression or denovo occurrence</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir +Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir 400 mg/day +ribavirin for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir+Simeprevir±Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir 400 mg/day +Simeprevir 150 mg/day ± ribavirin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir+Daclatasvir±Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir 400 mg/day +Daclatasvir 60 mg/day ± ribavirin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir+Ledipasvir±Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir 400 mg/day +Ledipasvir 90 mg/day ±ribavirin for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400 mg orally once daily</description>
    <arm_group_label>Sofosbuvir +Ribavirin</arm_group_label>
    <arm_group_label>Sofosbuvir+Simeprevir±Ribavirin</arm_group_label>
    <arm_group_label>Sofosbuvir+Daclatasvir±Ribavirin</arm_group_label>
    <arm_group_label>Sofosbuvir+Ledipasvir±Ribavirin</arm_group_label>
    <other_name>Sovaldi®</other_name>
    <other_name>GS-7977</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)</description>
    <arm_group_label>Sofosbuvir +Ribavirin</arm_group_label>
    <arm_group_label>Sofosbuvir+Simeprevir±Ribavirin</arm_group_label>
    <arm_group_label>Sofosbuvir+Daclatasvir±Ribavirin</arm_group_label>
    <arm_group_label>Sofosbuvir+Ledipasvir±Ribavirin</arm_group_label>
    <other_name>Copegus®</other_name>
    <other_name>Rebetol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <description>Simeprevir 150 mg orally once daily</description>
    <arm_group_label>Sofosbuvir+Simeprevir±Ribavirin</arm_group_label>
    <other_name>Olysio®</other_name>
    <other_name>TMC435</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daclatasvir</intervention_name>
    <description>Daclatasvir 60 mg orally once daily</description>
    <arm_group_label>Sofosbuvir+Daclatasvir±Ribavirin</arm_group_label>
    <other_name>clatazev®</other_name>
    <other_name>BMS-790052</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ledipasvir</intervention_name>
    <description>Ledipasvir 90 mg orally once daily</description>
    <arm_group_label>Sofosbuvir+Ledipasvir±Ribavirin</arm_group_label>
    <other_name>Co-formulated with Sofosbuvir in one tablet (Harvoni ® )</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-70 years old

          -  Confirmed HCV viremia by PCR

          -  CHILD Pugh &quot;A&quot; or &quot;B7,B8&quot;

          -  Confirmed HCC either by laboratory ,imaging or histopathological criteria

          -  Underwent or candidate for curative intervention for HCC (BCLC stage 0 ,A)

          -  Willing to be treated for HCV and signing informed consent

        Exclusion Criteria:

          -  Patients below 18 or above 70 years old

          -  patients with advanced liver condition &quot;CHILD score ≥ B9&quot;

          -  Patients with advanced HCC status (BCLC≥ B)

          -  Patients with combined HBV ,HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gamal Esmat, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aisha El Sharkawy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Hassany, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Hepatology &amp; Tropical Medicine Research Institute (NHTMRI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mai Mehrez, MD.</last_name>
    <role>Study Director</role>
    <affiliation>National Hepatology &amp; Tropical Medicine Research Institute (NHTMRI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amr Maged</last_name>
    <role>Study Chair</role>
    <affiliation>National Hepatology &amp; Tropical Medicine Research Institute (NHTMRI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Hassany, MD.</last_name>
    <phone>+2 01128500015</phone>
    <email>mohamadhassany@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aisha El Sharkawy, MD</last_name>
    <phone>+2 01222211004</phone>
    <email>a_m_sharkawy@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amr Maged</name>
      <address>
        <city>Cairo</city>
        <zip>11441</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amr Maged</last_name>
      <email>amrrasheed88@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>May 11, 2016</last_update_submitted>
  <last_update_submitted_qc>May 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Hepatology &amp; Tropical Medicine Research Institute</investigator_affiliation>
    <investigator_full_name>Mohamed Hassany</investigator_full_name>
    <investigator_title>Hepatology &amp; Gastroenterology Consultant , Director of HCC Unit</investigator_title>
  </responsible_party>
  <keyword>HCV-HCC-DAAs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>http://www.megafileupload.com/f3sT/Attachments_201656.zip</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

